Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenchuan Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8408-885X; OpenAlex author ID A5101784378. Sources: OpenAlex.

Their work

Papers
43 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 5 papers · 2019: 6 papers · 2020: 2 papers · 2021: 3 papers · 2022: 7 papers · 2023: 2 papers · 2024: 3 papers · 2025: 5 papers · 2026: 2 papers

Papers 43

  1. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  2. M1 Macrophage-derived TNF-α Promotes Pancreatic Cancer Ferroptosis via p38 MAPK-ACSL4 Pathway. Last author DOI 10.2174/0115665240374551250630075409↗
  3. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  4. CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. Co-author DOI 10.1002/ctm2.70501↗
  5. Effect of tumor microenvironment in pancreatic cancer on the loss of β-cell mass: implications for type 3c diabetes. Co-author DOI 10.1007/s00535-024-02204-w↗
  6. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  7. Pancreatic surgery is safe in elderly patients with PDAC. Co-author DOI 10.1186/s12877-025-05907-8↗
  8. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  9. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗
  10. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  11. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  12. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  13. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. Co-author DOI 10.1002/jhbp.1045↗
  14. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  15. Deep insight into lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.06.027↗
  16. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Last author DOI 10.1177/15353702211049220↗
  17. Commentary on "Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12148-1↗
  18. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Co-author DOI 10.21037/atm-22-1946↗
  19. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  20. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Co-author DOI 10.1007/s10147-020-01782-y↗
  21. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  22. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Last author DOI 10.1038/s41419-021-04293-4↗
  23. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Co-author DOI 10.1093/jjco/hyaa035↗
  24. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. Last author DOI 10.1111/jcmm.15500↗
  25. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  26. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  27. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111543↗
  28. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  29. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Last author DOI 10.21037/atm.2019.10.91↗
  30. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Last author DOI 10.7150/jca.35856↗
  31. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗
  32. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002234↗
  33. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Last author DOI 10.1186/s12967-018-1673-6↗
  34. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Co-author DOI 10.2217/fon-2017-0380↗
  35. Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes. Last author DOI 10.5114/ceji.2018.77381↗
  36. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Last author DOI 10.7150/jca.20917↗
  37. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pa… Co-author DOI 10.1007/s00262-015-1775-4↗
  38. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. First author DOI 10.1097/md.0000000000004527↗
  39. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Last author DOI 10.18632/oncotarget.10630↗
  40. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1007/s12032-014-0260-9↗
  41. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. First author DOI 10.1007/s13277-013-0679-1↗
  42. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗
  43. Primary small cell carcinoma of the pancreas: rare type of pancreatic cancer and review of the literatures. Co-author DOI 10.1186/1477-7819-10-32↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 22 shared papers, 2017–2026 · strength 3.22
  2. Hanlin Yin · 17 shared papers, 2018–2026 · strength 2.82
  3. Dansong Wang · 25 shared papers, 2012–2025 · strength 2.54
  4. Wenhui Lou · 18 shared papers, 2014–2026 · strength 2.53
  5. Qiangda Chen · 13 shared papers, 2019–2026 · strength 2.14
  6. Tiantao Kuang · 18 shared papers, 2012–2024 · strength 1.81
  7. Wenhui Lou · 13 shared papers, 2012–2024 · strength 1.53
  8. Dayong Jin · 16 shared papers, 2012–2024 · strength 1.42
  9. Yaolin Xu · 8 shared papers, 2018–2025 · strength 1.32
  10. Xuefeng Xu · 12 shared papers, 2017–2024 · strength 1.28
  11. Jun Yu · 7 shared papers, 2019–2025 · strength 1.10
  12. Yefei Rong · 11 shared papers, 2012–2024 · strength 0.97
  13. Wenhui Lou · 7 shared papers, 2013–2026 · strength 0.97
  14. Taochen He · 4 shared papers, 2024–2026 · strength 0.82
  15. Yun Jin · 3 shared papers, 2025–2026 · strength 0.64
  16. Yuan Ji · 4 shared papers, 2016–2025 · strength 0.62
  17. Jiande Han · 3 shared papers, 2024–2025 · strength 0.60
  18. Shanshan Gao · 6 shared papers, 2017–2022 · strength 0.57
  19. Jicheng Zhang · 3 shared papers, 2020–2026 · strength 0.57
  20. Wenquan Wang · 3 shared papers, 2023–2025 · strength 0.52
  21. Yueming Zhang · 3 shared papers, 2020–2025 · strength 0.51
  22. Zhihang Xu · 2 shared papers, 2025 · strength 0.41
  23. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  24. Liang Liu · 2 shared papers, 2024–2025 · strength 0.40
  25. Xi Guo · 3 shared papers, 2018–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.